Report from the 54th American Society of Hematology Annual Meeting and Exposition — Benign Hematology

Editors from Journal Watch Oncology and Hematology attended the 54th meeting of the American Society of Hematology (ASH) held in Atlanta from December 8 through 11, 2012. Here, Dr. David Green describes the latest findings in benign hematology.

Rivaroxaban Shortens Hospital Stays for Patients with Venous Thromboembolism

In the EINSTEIN trials (abstract 3419), 1781 hospitalized patients with deep vein thrombosis (DVT) and 4328 hospitalized patients with pulmonary embolism (PE) were randomized to receive either rivaroxaban (15 mg twice daily for 3 weeks followed by 20 mg once daily) or enoxaparin (1 mg/kg twice daily, overlapping with and followed by warfarin or acenocoumarol, goal international normalized ratio 2.0–3.0). The median hospital st…